Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is a life threatening global health problem with only two drugs available for treatment (benznidazole and nifurtimox), both having variable efficacy in the chronic stage of the disease and high rates of adverse drug react...
Saved in:
| Main Authors: | Jennifer Riley, Stephen Brand, Michael Voice, Ivan Caballero, David Calvo, Kevin D Read |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-09-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0004014&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
by: Lorna M MacLean, et al.
Published: (2018-07-01) -
The discovery of Trypanosoma cruzi and Chagas disease (1908-1909): tropical medicine in Brazil A descoberta do Trypanosoma cruzi e da doença de Chagas (1908-1909): medicina tropical no Brasil
by: Simone Petraglia Kropf, et al.
Published: (2009-07-01) -
An Update on Vaccines Against <i>Trypanosoma cruzi</i> and Chagas Disease
by: Nisha J. Garg
Published: (2025-01-01) -
Trypanosoma cruzi in wild mammals from an endemic area of Chagas disease on the coast of Ecuador
by: Ana Soto-Vivas, et al.
Published: (2025-08-01) -
Evaluation of the Vitros® Anti-T. cruzi assay for its incorporation into the Trypanosoma cruzi infection diagnostic algorithm
by: Miriam Campos-Ruiz, et al.
Published: (2024-12-01)